On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

ECHELON-2: Brentuximab Vedotin Combination Outperforms CHOP for Peripheral T-Cell Lymphomas

Results from the phase III ECHELON-2 trial showed that brentuximab vedotin added to a combination of cyclophosphamide, doxorubicin, and prednisone (BV+CHP) nearly doubled progression-free...

Selinexor Induces Deep Responses in Refractory Multiple Myeloma

More than one-quarter of patients with refractory multiple myeloma (MM) responded to treatment with a combination of selinexor and low-dose dexamethasone, according to results...

REACHing Children With Sickle Cell Anemia in Sub-Saharan Africa

Daily treatment with hydroxyurea was feasible, well-tolerated, and safe for children with sickle cell anemia (SCA) living in sub-Saharan Africa, according to results from...

Four Cycles as Effective as Six Cycles of Chemotherapy for Favorable-Risk DLBCL

While young patients with diffuse large B-cell lymphoma (DLBCL) are typically treated with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), results from...

Luspatercept Reduces the Need for Transfusions in Patients With Beta Thalassemia and MDS

In two separate phase III trials presented at the 2018 ASH Annual Meeting, luspatercept, a first-in-class recombinant fusion protein, was found to be safe...

New Drug Approvals in Nonmalignant Hematology

In 2018, the U.S. Food and Drug Administration (FDA) set a record for the number of approvals for new therapies – or new indications...

Algorithm Built on Big Data Improves Prognostic Accuracy Over Existing MDS Models

Using machine learning, researchers were able to develop a prognostic model that predicted survival among patients with myelodysplastic syndromes (MDS) and was more accurate...

Apixaban Superior to LMWH in Reducing Recurrence of Cancer-Associated VTE

Results from a trial presented at the 2018 ASH Annual Meeting add more support for the use of direct oral anticoagulants in patients with...

First-in-Human Trial Shows AMG 330 Is Tolerable in Relapsed/Refractory AML

AMG 330, an anti-CD33 bispecific T-cell engager (BiTE®) antibody construct, was generally tolerable and demonstrated anti-leukemic activity in patients with relapsed/refractory acute myeloid leukemia...

For Older Patients With CLL, Ibrutinib-Based Treatment Beats Standard Chemoimmunotherapy

Results from a randomized phase III study indicate that the Bruton tyrosine kinase (BTK) inhibitor ibrutinib with or without rituximab was superior to standard-of-care,...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.